Compare Heron Therapeutics Inc (HRTX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Growth Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Vanguard Growth Index Fund ETF trades at $91.99 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 5655.1× Heron Therapeutics Inc's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| HRTX | VUG | |
|---|---|---|
Market Cap | $68.01M | $384.60B |
Volume | 1,891,941 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $1.49 | $92.64 |
52-Week Low | $0.27 | $70.00 |
Typical Hold Time | 35 Days | 47 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
VUG trades at $92.42, down 0.24% with bullish technical signals from moving averages but bearish oscillators suggesting potential overbought conditions. The ETF maintains strong long-term performance with 12% average annual returns since inception, though current RSI levels indicate near-term caution. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings.
Long-term growth prospects remain favorable given VUG's historical outperformance and low 0.03% expense ratio. However, significant concentration risk in technology sector and elevated RSI levels present near-term headwinds. The ETF's value proposition centers on cost-efficient exposure to large-cap growth stocks for investors with multi-decade time horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
